NCT00319332View on ClinicalTrials.gov

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2005

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Lymphoma, Small Cleaved-Cell, FollicularLymphoma, Large-Cell, FollicularLymphoma, FollicularLymphoma, Non-Hodgkin
Interventions
DRUG

Ibritumomab Tiuxetan

DRUG

Iodine I 131 Tositumomab

Trial Locations (8)

14263

GSK Clinical Trials Call Center, Buffalo

29425

GSK Clinical Trials Call Center, Charleston

37920

GSK Clinical Trial Call Center, Knoxville

52242

GSK Clinical Trials Call Center, Iowa City

63110

GSK Clinical Trial Call Center, St Louis

97213

GSK Clinical Trial Call Center, Portland

98109

GSK Clinical Trial Call Center, Seattle

98431

GSK Clinical Trials Call Center, Tacoma

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY